John Paulson Paulson & Co
John Paulson is the founder of Paulson & Co., a firm that became world-famous for profits related to the 2007–2008 housing and credit crisis. Beyond that landmark trade, the firm has pursued merger arbitrage, event-driven, and opportunistic credit and equity strategies. Paulson remains one of the most recognized names in modern hedge fund history.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SOLS
Solstice Advanced Materials
SOLS
|
+$65.7M |
| 2 |
Bausch Health
BHC
|
+$16.4M |
| 3 |
Thryv Holdings
THRY
|
+$531K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$102M |
| 2 |
Honeywell
HON
|
+$42.1M |
| 3 |
TMQ
Trilogy Metals
TMQ
|
+$30.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.09% |
| 2 | Materials | 41.95% |
| 3 | Financials | 11.16% |
| 4 | Technology | 0.81% |
| 5 | Industrials | 0% |
Similar funds
John Paulson's Q4 2025 Portfolio in Review
As of Q4 2025, John Paulson held 11 positions worth $3.26B, up 9.9% from $2.97B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
John Paulson's Q4 2025 filing shows 1 new, 2 increased, 1 reduced and 2 closed positions. Its largest new stake was Solstice Advanced Materials: 1,395,787 shares worth $67.8M. The largest sale was Madrigal Pharmaceuticals, an estimated $102M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 45% a quarter earlier, followed by Materials and Financials.
- John Paulson's largest Q4 2025 buy was Solstice Advanced Materials: 1,395,787 shares worth $67.8M.
- John Paulson added most to Bausch Health in Q4 2025, an estimated $16.4M increase.
- John Paulson's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $102M.
- John Paulson fully exited Honeywell in Q4 2025, selling an estimated $42.1M.
- John Paulson's ten largest holdings make up 100% of its $3.26B portfolio in Q4 2025.
- John Paulson opened 1 new position and closed 2 in Q4 2025.
- John Paulson's portfolio value rose 9.9% quarter-over-quarter to $3.26B.
Based on Paulson & Co's 13F filing for Q4 2025, filed 17 Feb 2026.